AbbVie Company Profile (NYSE:ABBV)

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie announced a quarterly dividend on Friday, June 23rd. Stockholders of record on Friday, July 14th will be given a dividend of $0.64 per share on Tuesday, August 15th. This represents a $2.56 dividend on an annualized basis and a dividend yield of 3.43%. The ex-dividend date is Wednesday, July 12th. View AbbVie's Dividend History.

AbbVie declared that its Board of Directors has approved a share repurchase plan on Sunday, April 9th 2017, which permits the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to buy up to 5% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's board of directors believes its shares are undervalued.

AbbVie Inc. (NYSE:ABBV) posted its quarterly earnings results on Thursday, April, 27th. The company reported $1.28 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.26 by $0.02. The company earned $6.54 billion during the quarter, compared to analysts' expectations of $6.49 billion. AbbVie had a net margin of 24.07% and a return on equity of 148.83%. The business's quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the company earned $1.15 EPS. View AbbVie's Earnings History.

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, July, 28th 2017. View Earnings Estimates for AbbVie.

AbbVie issued an update on its FY17 earnings guidance on Thursday, April, 27th. The company provided EPS guidance of $5.44-5.54 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.49.

13 brokers have issued 12-month price targets for AbbVie's stock. Their predictions range from $60.00 to $94.00. On average, they anticipate AbbVie's share price to reach $74.58 in the next twelve months. View Analyst Ratings for AbbVie.

Here are some recent quotes from research analysts about AbbVie stock:

• 1. According to Zacks Investment Research, "AbbVie’s key drug Humira is performing well and should continue to be driven by growing awareness, favorable clinical data, new indications and expansion into new markets. Moreover, Imbruvica has multi-billion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. Investor focus will be on the stock with several late-stage data-readouts are expected in 2017. AbbVie’s shares outperformed the large-cap pharma industry so far this year. However, Viekira faces intense pricing and competitive pressure in the HCV market. Though Humira is doing well, the company is concerned about the product’s long-term prospects owing to the potential biosimilar competition. Estimates remained stable ahead of the company’s Q2 earnings release. AbbVie has had a mixed record of earnings surprises in the recent quarters. " (7/13/2017)
• 2. Jefferies Group LLC analysts commented, "ABBV's IPR with CHRS will be heard this week, which looks challenging in light of the prior institution decision. However, the market already expects ABBV to lose and we do not see the '135 patent alone as critical to delaying biosimilars, indicating positive asymmetry in our view. We look at the key IPR arguments as well as the risk/ reward around the decision expected in May as we prepare to attend the hearing." (2/14/2017)
• 3. Argus analysts commented, "strong" second quarter earnings print.The analysts noted that not only were AbbVie's results driven by sales of Humira and Imbruvica, but its pipeline also "strengthened" following the acquisition of Stemcentrix and a partnership with Boehringer Ingelheim for the commercial rights of a new immunology drug that is in a late stage trial.The analysts also stated that the earnings print confirmed Imbruvica's "rapid acceptance" which bodes well for future sales. Coupled with the Venclexta drug, AbbVie boasts two "powerful drugs" to treat first- and second-line CLL and other hematogical malignancies.Related Link: Investors Cheer AbbVie's Q2 Numbers, ForecastThe analysts also stated that AbbVie's stock is "attractively valued" at just 11.2x their 2017 earnings per share estimate, which is "well below" the average multiple of 14.5 of other companies under Argus' coverage.Finally, the analysts boosted their full-year 2016 adjusted earnings per share estimate to $4.84 from $4.80 and their 2017 earnings per share estimate to $5.95 from $5.90."The company has strengthened its product portfolio and pipeline through several deals over the past 12 months, and continues to post strong sales of Humira, aided by new indications," (8/8/2016)

AbbVie saw a decline in short interest during the month of June. As of June 30th, there was short interest totalling 24,405,917 shares, a decline of 16.2% from the June 15th total of 29,134,909 shares. Based on an average daily trading volume, of 6,120,148 shares, the short-interest ratio is currently 4.0 days. Approximately 1.5% of the company's shares are sold short.

Some companies that are related to AbbVie include ConvaTec Group PLC (CTEC), Mallinckrodt PLC (MNK), Indivior PLC (INDV), Supernus Pharmaceuticals (SUPN), Advanced Accelerator Applications S.A. (AAAP), Repligen (RGEN), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Eagle Pharmaceuticals (EGRX), Aimmune Therapeutics (AIMT), Rockwell Medical (RMTI), Assembly Biosciences (ASMB), Novan (NOVN), Check-Cap (CHEK), CorMedix (CRMD), DARA Biosciences (DARA), Macrocure Ltd (MCUR) and Salix Pharmaceuticals (SLXP).

AbbVie's management team includes the folowing people:

• Richard A. Gonzalez, Chairman of the Board, Chief Executive Officer
• William J. Chase, Executive Vice President, Chief Financial Officer
• Michael Severino M.D., Executive Vice President - Research & Development, Chief Scientific Officer
• Laura J. Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary
• Carlos Alban, Executive Vice President - Commercial Operations
• Henry O. Gosebruch, Executive Vice President, Chief Strategy Officer
• Timothy J. Richmond, Senior Vice President - Human Resources
• Azita Saleki-Gerhardt Ph.D., Senior Vice President - Operations
• Robert A. Michael, Vice President, Controller
• Robert J. Alpern M.D., Independent Director

AbbVie's stock is owned by many different of retail and institutional investors. Top institutional investors include US Bancorp DE (0.18%), Bank of Montreal Can (0.13%), APG Asset Management N.V. (0.10%), Chevy Chase Trust Holdings Inc. (0.09%), NN Investment Partners Holdings N.V. (0.09%) and National Pension Service (0.08%). Company insiders that own AbbVie stock include Carlos Alban, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Thomas A Hurwich, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

AbbVie's stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Atalanta Sosnoff Capital LLC, Armstrong Shaw Associates Inc. CT, Exxonmobil Investment Management Inc. TX, Sit Investment Associates Inc., Nisa Investment Advisors LLC, Factory Mutual Insurance Co. and Meeder Asset Management Inc.. Company insiders that have sold AbbVie stock in the last year include Carlos Alban, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

AbbVie's stock was bought by a variety of institutional investors in the last quarter, including Mn Services Vermogensbeheer B.V., NN Investment Partners Holdings N.V., Pennsylvania Trust Co, National Pension Service, GW&K Investment Management LLC, Manning & Napier Advisors LLC, Aperio Group LLC and Bank of Montreal Can. View Insider Buying and Selling for AbbVie.

Shares of AbbVie can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of AbbVie stock can currently be purchased for approximately $74.63.